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Two entities are considered in this edi-
torial: one is a bacterium and the other
a clinical infection, but it is their re-
lationship that is the issue of interest.
Originally referred to as micrococcus,
Staphylococcus aureus has been a recog-
nized problem for well over a century.
It is a frequent colonizer of skin and
mucosa in animals and humans. In hu-
mans, the preferred niche is the anterior
nares, although it can also be frequently
found in the axillae and perineum. Nasal
carriage rates in the general population
vary from 10% to 40%.
Staphylococcus aureus is also a highly
successful pathogen responsible for a vari-
ety of clinical problems ranging from
folliculitis to endocarditis, osteomyelitis
to pneumonia, and food intoxication to
septic shock. A number of structural and
secreted virulence factors play a role in
the pathogenesis of these various con-
ditions and the evasion of host defenses.
Penicillinase-resistant semisynthetic
penicillins, such as methicillin, became
available in the late 1950s. Shortly
thereafter, methicillin-resistant strains of
S. aureus appeared [1]. The development
of such strains is likely related to the ac-
quisition of staphylococcal cassette chro-
mosome (SCC)mec allotypes. SCCmec is
an acquired fragment of DNA that carries
b-lactam resistance genes and may also
carry resistance genes to additional an-
tibiotics. This early appearance of an-
tibiotic resistance was a harbinger of
things to come, and methicillin-resistant
S. aureus (MRSA) has been a growing
problem in hospital-acquired infections
for some time. More recently, community-
associated MRSA (CA-MRSA) infections
have been described in patients with skin
and soft tissue infections and pneumonia
and is a cause of growing concern.
Community-acquired pneumonia (CAP)
is not a reportable disease, and therefore
accurate ﬁgures are not available. Data
from the United States suggest that there
are.4millioncasesperyear,resultingin
.600000hospitalizations,64milliondays
of restricted activity, and 50 000 deaths
annually [2]. The overall yearly cost as-
sociated with CAP in the United States is
estimated to be $9–$10 billion dollars.
CAP is often misdiagnosed and im-
properly treated. When confronted with
a patient with possible CAP, there are 2
questions to be answered. First, is the
clinical syndrome in fact pneumonia or
some other clinical entity? Second, if
CAP, what is the etiologic pathogen?
The diagnosis of pneumonia itself is
based on a compatible history and the
presence of select clinical features plus
a chest radiographic abnormality.
The lack of rapid, sensitive, and spe-
ciﬁc methods to determine the etiologic
agent in a particular patient means that
the attending physician must often ini-
tiate antimicrobial treatment without
knowing the pathogen with any degree
of certainty. Given the large number of
potential pathogens including bacteria,
atypical bacteria, and viruses, uncertainty
regarding etiology represents a signiﬁcant
problem, particularly for patients ill
enough to require admission to hospital.
For those requiring management in an
intensive care unit (ICU) setting, correct
initial selection of an antimicrobial regi-
men assumes critical importance because
of the high mortality rates seen in such
cases.
Although it was clear that MRSA was
becoming an important pathogen in
cases of hospital-acquired pneumonia
and ventilator-associated pneumonia,
it is currently considered to be the etio-
logic agent in 20%–40% of such cases
[3, 4]. As might be expected, the situ-
ation seemed to be quite different for
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uncommon, typically occurring as a su-
perinfection in patients with inﬂuenza and
overall accounting for infection in only
1%–5% of all CAP patients.
A sharp increase in MRSA infection
in patients without obvious exposure to
the healthcare system led to the recog-
nition of the new clones referred to as
CA-MRSA. CA-MRSA with its SCCmec
type IV, and usually with a gene for
Panton-Valentine leukocidin, has been
responsible for a variety of infections
with the majority of isolates in the
United States being pulsed-ﬁeld type
USA300 [5].
T h ep r e v a l e n c eo fC A - M R S Av a r i e sb e t -
ween countries and even within national
boundaries. The community-associated
variant has characteristics that distinguish
it somewhat from its hospital-acquired
counterpart, including susceptibility to
certain antibiotics (eg, clindamycin, tri-
methoprim/sulfamethoxazole, and doxy-
cycline) and differing epidemiologic risk
f a c t o r ss u c ha so c c u r r e n c ei na t h l e t e s ,g a y
men, and patients with concurrent skin
and soft tissue infections. More recently,
CA-MRSA infections have begun to move
from the community setting into the
healthcare setting and no longer seem
to be restricted to certain risk groups
or to geographic locales where outbreaks
ﬁrst occur [4, 6].
The paper by Moran et al in this issue
of Clinical Infectious Diseases provides
important information regarding CA-
MRSA CAP [7]. This prospective obser-
vational study was designed to determine
the properties of adults with MRSA-
related CAP who were hospitalized
through the emergency department and
to identify factors associated with such
infections. Until very recently, most
data on CAP caused by MRSA were
provided by case series. According to
one paper, ‘‘clinical presentation is usually
that of a severe pneumonia with high fe-
ver, hypotension, and hemoptysis fol-
lowed by rapid progression to septic shock
and requirement for ventilator support’’
[6]. Papers from the United States and
Europe have reported mortality rates
.50% [8–10].
A 2010 paper by Lobo et al, however,
disputed such ﬁndings [11]. In contrast
to prior studies, they found (1) signif-
icantly lower mortality rates (13.3%),
(2) medical care required for only ap-
proximately half of patients, (3) an ab-
sence of ﬁndings previously attributable
to CA-MRSA including hemoptysis and
neutropenia, and (4) no relationship to
inﬂuenza.
The Moran study adds to the Lobo
data by ﬁnding that mortality rates (14%)
were lower than expected and that clini-
cal and epidemiologic factors thought to
be associated with MRSA infection did
not help in deciding initial empirical
antibiotic therapy.
The Moran study appears carefully
planned and executed and has a number
of positive features. It was carried out in
12 different cities around the United
States, which hopefully mitigates regional
variations in incidence of MRSA. Most
important, by providing both numerator
and denominator, they put the frequency
of MRSA as a CAP pathogen into per-
spective by reporting it in only 2.4% of
patients and 5% of patients admitted to
the ICU. They did note, however, that, in
general, patients with infection caused by
MRSA tended to be sicker at the time of
presentation and were more likely to re-
quire intubation or pressors or to die in
the emergency department.
The few weaknesses of the paper are
relatively minor. It would have been nice
to know the results of urine antigen or
serologic testing for atypical pathogens
and nasopharyngeal viral molecular test-
ing to get an idea of their prevalence and
to determine if MRSA can be a copath-
ogen with them. The incidence may be
slightly underestimated; only the peak
pneumonia season was included, and
CA-MRSA infections appear to have no
seasonal variation [12]. Also, the authors
failed to provide a deﬁnition of severe
CAP used for ICU admission. Are they
using the CURB criteria or the Pneu-
monia Severity Index score or a func-
tional deﬁnition based on requirements
for mechanical ventilation and/or vas-
opressors [13–15]? Finally, the fact that
all 12 sites were university-afﬁliated
centers may make their data and con-
clusions less generalizable than if both
community-based and academic centers
been involved.
In the end, however, we still have
a problem. The good news seems to be
that MRSA CAP may not be as common
or severe as previously thought—but
how does the average physician decide
when to treat with anti-MRSA drugs?
Certainly, the risk is higher for those ill
enough to require ICU admission; how-
ever, should all severe CAP cases be
treated for MRSA for an average of only
slightly .1 patient per hospital per
season? What about those patients who
are not as sick? If not treated appropri-
ately initially, will patients who actually
have CA-MRSA CAP do signiﬁcantly
worse?
In selecting a particular antibiotic
regimen, what is the best agent? Because
part of the pathogenesis of S. aureus
infections is dependent upon exotoxins,
then perhaps drugs that suppress toxin
production may be important for seri-
ous CA-MRSA infections. Lobo et al
mention both linezolid and clindamycin
because both can inhibit exotoxin pro-
duction [11]. We are certainly in favor
of linezolid for treatment of CAP caused
by MRSA. As for clindamycin, how-
ever, Moran et al found that 18% of
their isolates were clindamycin resistant.
While this rate is certainly disconcerting,
49%–76% of such isolates were clinda-
mycin resistant in a Boston healthcare
facility [16]. Whether antibiotic sensitivity
testing correlates with toxin-suppression
activity is also unclear.
Only prospective interventional tri-
a l sw i l la n s w e rt h eq u e s t i o n so fo p t i m a l
treatment. However, the study of Moran
et al presents data critical to the design
a n dp o w e r i n go fs u c ht r i a l s .T h ea u t h o r s
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service for patients, clinicians, and clinical
researchers.
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